Autolus Therapeutics
AUTL
111 hedge funds and large institutions have $620M invested in Autolus Therapeutics in 2024 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 39 increasing their positions, 31 reducing their positions, and 24 closing their positions.
75% more call options, than puts
Call options by funds: $121K | Put options by funds: $69K
26% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 31
0.86% more ownership
Funds ownership: 66.1% → 66.97% (+0.86%)
8% less funds holding
Funds holding: 121 → 111 (-10)
38% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 24
45% less capital invested
Capital invested by funds: $1.12B → $620M (-$501M)
60% less funds holding in top 10
Funds holding in top 10: 5 → 2 (-3)
Top Buyers
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$30.8M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$14.1M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$9.82M |
| 4 |
Morgan Stanley
New York
|
+$9.56M |
| 5 |
AC
Armistice Capital
New York
|
+$6.81M |
Top Sellers
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$42.2M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
-$41M |
| 3 |
PA
Perceptive Advisors
New York
|
-$27.6M |
| 4 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
-$8.87M |
| 5 |
FAM
Fred Alger Management
New York
|
-$5.12M |
AUTL Hedge Fund Activity: Q2 2024 in Review
111 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Autolus Therapeutics (AUTL) for Q2 2024, worth a combined $620M — down 45% from $1.12B a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of AUTL and 15 opened new positions — a net loss of 9 holders — while 31 trimmed existing stakes and 39 added.
The largest buyer was Wellington Management Group, adding an estimated $30.8M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $42.2M sold.
- 111 institutional investors held Autolus Therapeutics (AUTL) as of Q2 2024, down from 121 in Q1 2024.
- Funds reported $620M of Autolus Therapeutics stock for Q2 2024, down 45% quarter-over-quarter.
- 15 funds opened new Autolus Therapeutics positions in Q2 2024 and 24 closed out, a net change of -9 holders.
- The largest Autolus Therapeutics buyer in Q2 2024 was Wellington Management Group, an estimated $30.8M added.
- The largest Autolus Therapeutics seller in Q2 2024 was Cormorant Asset Management, an estimated $42.2M sold.
Based on aggregated 13F filings for Q2 2024.